Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

1.8K
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
1.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoantigen-loaded Polymeric Microparticles associate with B cells and promote tolerogenic antigen presentation in a mouse model of experimental autoimmune encephalomyelitis.

Nature communications·2026
Same author

Single-cell gain-of-function mapping reveals latent regulatory programs governing CD8+ T cell fate.

Research square·2026
Same author

Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function.

Clinical lymphoma, myeloma & leukemia·2026
Same author

High-avidity cathepsin-G-specific CAR-T cells for the treatment of acute myeloid leukemia.

Blood·2026
Same author

NG2-targeting macrophages inhibit 3D invasion of patient-derived glioblastoma spheroids.

bioRxiv : the preprint server for biology·2026
Same author

Publisher Correction: Atlas-guided discovery of transcription factors for T cell programming.

Nature·2026
Same journal

GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing.

Translational research : the journal of laboratory and clinical medicine·2026
Same journal

Activating transcription factor 3 aggravates renal fibrosis by regulating EGR2-mediated autophagy.

Translational research : the journal of laboratory and clinical medicine·2026
Same journal

Extracellular Vesicles in the Tumor Microenvironment: Diverse Origins, Multifaceted Functions, and Emerging Therapeutic Opportunities.

Translational research : the journal of laboratory and clinical medicine·2026
Same journal

Circ_QRICH1 promotes osteoarthritis progression by sponging miR-214-3p to impact ATF3-mediated chondrocyte ferroptosis.

Translational research : the journal of laboratory and clinical medicine·2026
Same journal

Letter to the Editor: Reflections on "Auricular Vagus Nerve Stimulation Alleviates Cardiac Dysfunction in Takotsubo Syndrome".

Translational research : the journal of laboratory and clinical medicine·2026
Same journal

SynNotch-iNOS CAR-Macrophages Remodel the Tumor Immune Microenvironment and Exhibit Antitumor Efficacy via a CD4<sup>+</sup> T Cell-Dependent Mechanism.

Translational research : the journal of laboratory and clinical medicine·2026
See all related articles

Related Experiment Video

Updated: Feb 26, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.2K

Chimeric antigen receptor T-cells for B-cell malignancies.

Eben I Lichtman1, Gianpietro Dotti2

  • 1Department of Medicine, University of North Carolina, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.

Translational Research : the Journal of Laboratory and Clinical Medicine
|July 19, 2017
PubMed
Summary
This summary is machine-generated.

Chimeric antigen receptor T-cell (CAR-T) therapy shows promise for B-cell cancers, but toxicities and product variability require further research. Ongoing studies explore new CAR-T designs and strategies to improve patient outcomes.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K

Related Experiment Videos

Last Updated: Feb 26, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.2K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K

Area of Science:

  • Immunotherapy
  • Oncology
  • Cellular Therapy

Background:

  • Adoptive transfer of T-lymphocytes engineered with chimeric antigen receptors (CAR-Ts) has demonstrated significant clinical efficacy in B-cell malignancies.
  • The field has seen rapid growth, with numerous clinical trials investigating CAR-T therapies.
  • While CD19-specific CAR-Ts are widely studied, other B-cell targets are also being explored.

Purpose of the Study:

  • To review the background and rationale for CAR-T therapy in B-cell malignancies.
  • To provide an overview of current advancements in CAR-T technology and application.
  • To examine the clinical trial landscape for CAR-T treatments in B-cell cancers.

Main Methods:

  • Review of existing literature on CAR-T therapy for B-cell malignancies.
  • Analysis of clinical trial data and preclinical research findings.
  • Discussion of CAR designs, production strategies, and associated toxicities.

Main Results:

  • CAR-T therapy has yielded impressive clinical responses in B-cell malignancies.
  • Significant heterogeneity exists among CAR-T products, influencing clinical outcomes.
  • Toxicities associated with CAR-T administration remain a critical concern.

Conclusions:

  • CAR-T therapy represents a promising approach for treating B-cell malignancies.
  • Further research is needed to address product variability and mitigate toxicities.
  • Ongoing and preclinical studies are crucial for optimizing CAR-T strategies and improving patient outcomes.